Table 1.
Baseline demographic and disease characteristics
| Characteristic | Etanercept + placebo (n = 239) | Etanercept + methotrexate (n = 239) |
|---|---|---|
| Male sex, n (%) | 167 (69·9) | 153 (64·0) |
| Race, n (%) | ||
| White | 177 (74·1) | 179 (74·9) |
| Black | 10 (4·2) | 4 (1·7) |
| Hispanic | 39 (16·3) | 42 (17·6) |
| Asian | 9 (3·8) | 10 (4·2) |
| Other | 4 (1·7) | 4 (1·7) |
| Age (years), mean (SD) | 45·2 (12·8) | 43·0 (13·1) |
| Median (Q1, Q3) | 45·0 (36·0, 55·0) | 43·0 (33·0, 52·0) |
| Weight (kg), mean (SD) | 95·8 (24·5) | 93·6 (24·2) |
| Median (Q1, Q3) | 93·0 (79·6, 109·1) | 89·0 (77·0, 104·0) |
| Height (cm), mean (SD) | 172·0 (10·1) | 170·8 (10·5) |
| Median (Q1, Q3) | 172·7 (165·1, 177·8) | 172·7 (164·0, 177·8) |
| BMI (kg m−2), mean (SD) | 32·3 (7·5) | 32·2 (8·1) |
| Median (Q1, Q3) | 31·1 (27·1, 35·8) | 30·9 (27·2, 35·6) |
| ≤ 35 kg m−2, n (%) | 173 (72·4) | 172 (72·0) |
| > 35 kg m−2, n (%) | 66 (27·6) | 67 (28·0) |
| Psoriasis BSA affected, %, mean (SD) | 24·2 (13·6) | 24·4 (15·9) |
| Median (Q1, Q3) | 20·5 (14·0, 30·0) | 18·5 (13·8, 30·0) |
| PASI, mean (SD) | 18·3 (6·6) | 18·2 (8·2) |
| Median (Q1, Q3) | 17·1 (13·3, 21·4) | 15·9 (12·6, 21·9) |
| sPGA, n (%) | ||
| Unknown | 1 (0·4) | 0 (0) |
| 0 | 0 (0) | 0 (0) |
| 1 | 1 (0·4) | 0 (0) |
| 2 | 24 (10·0) | 32 (13·4) |
| 3 | 139 (58·2) | 138 (57·7) |
| 4 | 68 (28·5) | 60 (25·1) |
| 5 | 6 (2·5) | 9 (3·8) |
| Duration of psoriasis, years, mean (SD) | 16·9 (12·7) | 17·9 (12·7)a |
| Median (Q1, Q3) | 14·7 (6·0, 25·8) | 15·8 (7·4, 26·0) |
| History of psoriatic arthritis, n (%) | 50 (20·9) | 58 (24·3) |
| Prior psoriasis therapy, n (%) | 217 (90·8) | 220 (92·1) |
| Prior systemic therapy, n (%) | 100 (41·8) | 108 (45·2) |
| Methotrexate | 38 (15·9) | 44 (18·4) |
| Oral retinoids | 10 (4·2) | 15 (6·3) |
| Steroids | 10 (4·2) | 14 (5·9) |
| Prior TNF-blocker therapy, n (%) | 48 (20·1) | 42 (17·6) |
| Etanercept | 35 (14·6) | 32 (13·4) |
| Adalimumab | 13 (5·4) | 10 (4·2) |
| Prior phototherapy, n (%) | 66 (27·6) | 84 (35·1) |
| UVB | 55 (23·0) | 66 (27·6) |
| PUVA | 15 (6·3) | 25 (10·5) |
| Prior topical nonsteroid use, n (%) | 122 (51·0) | 135 (56·5) |
| Vitamin D analogues | 74 (31·0) | 78 (32·6) |
| Tar compounds | 66 (27·6) | 66 (27·6) |
| Prior topical steroid use, n (%) | 180 (75·3) | 164 (68·6) |
| Other | 123 (51·5) | 120 (50·2) |
| Taclonex® (Leo Pharma Ballerup, Denmark): betamethasone+calcipotriene | 86 (36·0) | 72 (30·1) |
| Lotrisone® (Merck, Whitehouse Station,NJ, U.S.A.): betamethasone+clotrimazole | 25 (10·5) | 15 (6·3) |
BMI, body mass index; BSA, body surface area; PASI, Psoriasis Area and Severity Index; Q1, first quartile; Q3, third quartile; sPGA, static Physician’s Global Assessment; TNF, tumour necrosis factor; UVB, ultraviolet B; PUVA, psoralen plus UVA.
a
One patient had stable moderate to severe plaque psoriasis for 0·4 years.